About

Jacquelyn grew up on a rural family farm in Wisconsin where she learned the value of hard work and self sufficiency during her childhood years. They grew their own food in a large vegetable garden and also used animals to provide dairy and meat for the family and community. Jacquelyn spent countless hours exploring the woods, learning how to identify edible wild mushrooms, leeks, berries, walnuts, apples, plums, asparagus and other items that could be easily foraged.

Jacquelyn was also very studious and one of the few people in her family to attend college. She worked and paid for her own education, including college, medical school and residency/fellowship. She graduated with very little debt and used extensive education and training to give back to society since she was so fortunate to be blessed with so many opportunities.

Jacquelyn came to Duluth Minnesota because there was not a pediatric oncology program in 2002. When she arrived, her desire was to start a state of the art pediatric oncology program. Prior to this children and their families would be dislocated to tertiary care centers hours away in order to receive cancer care. This treatment could last years in some cases.

Jacquelyn successfully built a program in Duluth from the ground up over the last 20 years. She  took non-stop calls and did patient care 24/7 for years, but as the support for the program grew she was able to add on more physicians and practitioners. Jacquelyn also started a pediatric and adult survivorship program to follow long term survivors of cancer. The final goal was achieved in 2021 when a Ronald McDonald house was in place!

Jacquelyn loved her job as a pediatric hematologist/oncologist, but found that traditional allopathic medical care was no longer providing solutions to many of the health challenges that were increasing over the last 20 years. Therefore,  she expanded her training to include a certification by the Institute of Functional Medicine and an additional certification in Obesity/Weight Management medicine.

This additional lifestyle, wholistic medical training has brought a full circle to what she loved as a child- using nature, God’s creation, fresh air and exercise and other natural solutions to promote health. Now, twenty years later the pediatric hematology/oncology program is strong and provides a valuable resource to the community. Therefore, it is again time to trail blaze another path in the Duluth area and help the community find wholistic solutions to encourage intrinsic healing that the body is designed for to achieve health naturally. 

Wiermaa_Jacquelyn_5930_19_PBL.jpg
Jacquelyn-Wiermaa,-MD-black-high-res.png
press to zoom
IMG_3301_edited
press to zoom
press to zoom
press to zoom
press to zoom
press to zoom
1/1

Fellowship (2002)

Children's Hospital Medical Center
Cincinnati, Ohio

Pediatric Hemotology - Oncology

Master's Degree (2002)

University of Cincinnati

Degree Earned: Master’s of Science (Epidemiology)

Residency (1999)

Medical College of Wisconsin Affiliated Hospitals

American Academy of Pediatrics Resident Delegate for the Medical College of Wisconsin Pediatric Residency

Medical Education (1996)

Medical College of Wisconsin

Alpha Omega Alpha Medical Honor Society William Douglas Brooker Award in Pharmacology Recognition of Academic Excellence and Ranking first Among the Class, 1996

American Medical Women’s Association Scholarship Achievement Award, May 17, 1996

American Society of Clinical Pathologist’s Award for Academic Excellence and Achievement, June 1994

Bachelor of Science (1992)

University of Wisconsin La Crosse

Biology (Major)

Graduated With Highest Honors 

McIlraith Biology Award

Dean’s List Eight out of Eight Consecutive Semesters

Senior of the Year Award, 2nd Runner Up

 

Low Dose Naltrexone Trained Provider - 2022

International Foundation For Nutrition and Health Member - 2022

Obesity Medicine Board Certification - March 2022

Certified Practitioner – Institute of Functional Medicine - 2021

Children's Oncology Group Member - 2000-2021

National Pediatric Hypnosis Training (NPHTI) 2014

American Board of Pediatric Hematology/Oncology sub-specialty boards: Passed 2002

American Board of Pediatrics Licensing Examination: Passed 2000

USMLE Step I Score: 236 (97th Percentile)

USMLE Step II Score: 250 (99th Percentile)

USMLE Step III Score: 230

Certifications

 

Approved Grants

These grants were approved to fund the Oncology and Survivorship program at Essentia Health, Duluth, MN. 
Grants are written repeatedly as needed to St. Mary's Auxiliary to fund gas cards and meal reimbursement for families affected by their child receiving cancer treatment. 
 
AdobeStock_58708006.jpeg

Clinical Research

 Jacquelyn participated in many research studies and helped patients into the programs necessary 
Children's Oncology Group Research Studies

 A Phase III Randomized Trial for Newly Diagnosed High-Risk B-precursor Acute Lymphoblastic Leukemia (ALL) Including a Stratum Evaluating Dasatinib in Patients with Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations. (COG AALL1131)

A Phase III, Randomized Clinical Trial Testing Nelarabine in Newly, Diagnosed T-Cell Acute Lymphoblastic Leukemia. (COG AALL0434)

A study to compare the addition of Blinatumomab in combination with chemotherapy in patients diagnosed with standard-risk B-cell Acute Lymphoblastic Leukemia (B-ALL), Down syndrome B ALL and the treatment of patients with localized B-cell Lymphoma. (COG AALL1731)

Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia (COG AALL0232)

A Phase III Study for Patients with Newly Diagnosed Acute Promyelocytic Leukemia (APL) using Arsenic Trioxide and All Trans-Retinoic Acid (COG AAML1331)

 

Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome (COG AAML1531)

 

A Randomized Phase 3 Study of Brentuximab Vedotin (SGN-35, IND #117117) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Young Adults (COG AHOD1331)

A Phase III Study of Dose-Intensive Therapy for Intermediate-Risk Hodgkin Lymphoma (COG AHOD0031)

 

Combination Chemotherapy and Radiation Therapy in Treating Patients With Acute Lymphoblastic Leukemia That Has Relapsed in the CNS or Testes (COG AALL02P2)

 

The Treatment of Down syndrome Children with Acute Myeloid Leukemia and MDS Under the Age of 4 Years (COG AAML0431)

 

A phase 3 Study for Patients with High-Risk Medulloblastoma and/or PNET (COG ACNS0332)

 

 A phase 3 Randomized Trial of Post-Radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma Ages 1-21 years (COG ACNS0831)

A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children with De Novo High-Risk (HR) Cytokine Receptor-Like Factor 2-Rearranged (CRLF2-R) and/or Janus Kinase (JAK) Pathway-Mutant Acute Lymphoblastic Leukemia (ALL) (COG AALL1521)

 

 A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors (COG AGCT1531)

 

Late Effects After High-Risk Neuroblastoma (LEAHRN) Study (COG ALTE15N2) 

Utilizing Response and Biology Based Risk Factors to Guide Therapy in Patients with Non-High Risk Neuroblastoma (COG ANBL1232)

A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Standard Thera[y for Children with Newly Diagnosed High-Risk Neuroblastoma (COG ANBL1531)